Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert F Lobuglio

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 17, 2009
Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphomaSui Shen, Andres Forero, Ruby F Meredith, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 28, 2013
Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphomaChristos Vaklavas, Ruby F Meredith, Sui Shen, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 27, 2005
Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administrationAndres Forero, Ruby F Meredith, M B Khazaeli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
Intraperitoneal pretarget radioimmunotherapy with CC49 fusion proteinDonald J Buchsbaum, M B Khazaeli, Donald B Axworthy, et al.
Cancer Biology & Therapy|September 1, 2009
Epithelial transformation by KLF4 requires Notch1 but not canonical Notch1 signalingZhaoli Liu, Lihong Teng, Sarah K Bailey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinomaJames A Posey, Thian C Ng, Baolian Yang, et al.
Plos One|September 22, 2011
Cellular model of Warburg effect identifies tumor promoting function of UCP2 in breast cancer and its suppression by genipinVanniarajan Ayyasamy, Kjerstin M Owens, Mohamed Mokhtar Desouki, et al.
Human Gene Therapy|February 11, 2005
Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanomaPierre L Triozzi, Theresa V Strong, R Pat Bucy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patientsRobert M Conry, David T Curiel, Theresa V Strong, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 27, 2005
Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 regionBuck E Rogers, Peter L Roberson, Sui Shen, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 17, 2009
Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphomaSui Shen, Andres Forero, Ruby F Meredith, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 28, 2013
Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphomaChristos Vaklavas, Ruby F Meredith, Sui Shen, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 27, 2005
Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administrationAndres Forero, Ruby F Meredith, M B Khazaeli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
Intraperitoneal pretarget radioimmunotherapy with CC49 fusion proteinDonald J Buchsbaum, M B Khazaeli, Donald B Axworthy, et al.
Cancer Biology & Therapy|September 1, 2009
Epithelial transformation by KLF4 requires Notch1 but not canonical Notch1 signalingZhaoli Liu, Lihong Teng, Sarah K Bailey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinomaJames A Posey, Thian C Ng, Baolian Yang, et al.
Plos One|September 22, 2011
Cellular model of Warburg effect identifies tumor promoting function of UCP2 in breast cancer and its suppression by genipinVanniarajan Ayyasamy, Kjerstin M Owens, Mohamed Mokhtar Desouki, et al.
Human Gene Therapy|February 11, 2005
Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanomaPierre L Triozzi, Theresa V Strong, R Pat Bucy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patientsRobert M Conry, David T Curiel, Theresa V Strong, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 27, 2005
Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 regionBuck E Rogers, Peter L Roberson, Sui Shen, et al.
Pageof 6